Intuitive interventional cardiology platform combines the most comprehensive set of diagnostic and treatment planning tools to help support confident decisions and improved patient care
With FDA clearance and CE marking, IntraSight Plus...
Intuitive interventional cardiology platform combines the most comprehensive set of diagnostic and treatment planning tools to help support confident decisions and improved patient care
With FDA clearance and CE marking, IntraSight Plus...
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
The study found that AK-AVS can detect aortic stenosis through routine ECGs up to 4.5 years before TAVR intervention, potentially enabling earlier detection, easier-to-access monitoring, and better timing of intervention.
The study found that AK-AVS can detect aortic stenosis through routine ECGs up to 4.5 years before TAVR intervention, potentially enabling earlier detection, easier-to-access monitoring, and better timing of intervention.
Salus Scientific and Tallahassee Memorial HealthCare (TMH) announced the successful implementation and first clinical use of AeroShield™, a groundbreaking radiation protection technology developed by Salus Scientific.
Salus Scientific and Tallahassee Memorial HealthCare (TMH) announced the successful implementation and first clinical use of AeroShield™, a groundbreaking radiation protection technology developed by Salus Scientific.
Sunnyvale, California – Avantec Vascular, a NIPRO Company, has received FDA 510(k) clearance for a thrombectomy system that will enable a new type of treatment for patients with thrombus in the peripheral venous...
Sunnyvale, California – Avantec Vascular, a NIPRO Company, has received FDA 510(k) clearance for a thrombectomy system that will enable a new type of treatment for patients with thrombus in the peripheral venous...
New York, NY – Mount Sinai researchers have identified a cellular mechanism linking infections from influenza A viruses (IAVs) to cardiovascular disease, providing critical insights on how influenza can damage the heart and increase the risk...
New York, NY – Mount Sinai researchers have identified a cellular mechanism linking infections from influenza A viruses (IAVs) to cardiovascular disease, providing critical insights on how influenza can damage the heart and increase the risk...
The HOTWIRE™ Transseptal Access System combines a novel RF guidewire with a next-generation RF generator designed to optimize transseptal access, streamline procedural workflows and improve patient outcomes with the best-in-class platform for...
The HOTWIRE™ Transseptal Access System combines a novel RF guidewire with a next-generation RF generator designed to optimize transseptal access, streamline procedural workflows and improve patient outcomes with the best-in-class platform for...
Penumbra recently launched the Lightning Flash® 3.0 Computer Assisted Vacuum Thrombectomy (CAVT™) system, which includes significant upgrades that further advance our leading venous thromboembolism (VTE) platform.
Penumbra recently launched the Lightning Flash® 3.0 Computer Assisted Vacuum Thrombectomy (CAVT™) system, which includes significant upgrades that further advance our leading venous thromboembolism (VTE) platform.
New York, NY – In the lead-up to American Heart Health Month, a new national study reveals a stark disconnect between Americans’ desire for preventive cardiac screening and the care they can access. Despite heart disease remaining the leading...
New York, NY – In the lead-up to American Heart Health Month, a new national study reveals a stark disconnect between Americans’ desire for preventive cardiac screening and the care they can access. Despite heart disease remaining the leading...
Intuitive interventional cardiology platform combines the most comprehensive set of diagnostic and treatment planning tools to help support confident decisions and improved patient care
With FDA clearance and CE marking, IntraSight Plus...
Intuitive interventional cardiology platform combines the most comprehensive set of diagnostic and treatment planning tools to help support confident decisions and improved patient care
With FDA clearance and CE marking, IntraSight Plus...
A new school partnership between Sutter Health and Sacramento Ultrasound Institute has been created to empower and upskill Cath Lab team members—launched recently at Memorial Medical Center in Modesto, California.
A new school partnership between Sutter Health and Sacramento Ultrasound Institute has been created to empower and upskill Cath Lab team members—launched recently at Memorial Medical Center in Modesto, California.
In this interview from CRT 2026, Dr Garima Wadhwani discusses her Top Abstract evaluating left atrial appendage occlusion as a safer alternative to oral anticoagulation for select atrial fibrillation patients with cirrhosis.
In this interview from CRT 2026, Dr Garima Wadhwani discusses her Top Abstract evaluating left atrial appendage occlusion as a safer alternative to oral anticoagulation for select atrial fibrillation patients with cirrhosis.
In this session from CRT 2026, Dr Nassir F. Marrouche of Tulane University presented the latest evidence positioning pulsed field ablation as a transformative advance in AF ablation.
In this session from CRT 2026, Dr Nassir F. Marrouche of Tulane University presented the latest evidence positioning pulsed field ablation as a transformative advance in AF ablation.
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
In this CRT 2026 interview, Dr Andreas Sarantopoulos of the NCH Rooney Heart Institute discusses his Top Abstract on machine learning for predicting recurrent atrial fibrillation and its implications for interventional cardiology practice.
In this CRT 2026 interview, Dr Andreas Sarantopoulos of the NCH Rooney Heart Institute discusses his Top Abstract on machine learning for predicting recurrent atrial fibrillation and its implications for interventional cardiology practice.
In his session at CRT 2026, Dr Eric Secemsky reviewed contemporary data linking sympathetic overactivity to heart failure, atrial fibrillation, and cardiometabolic disease, and examined how renal and multi-organ denervation may modify these...
In his session at CRT 2026, Dr Eric Secemsky reviewed contemporary data linking sympathetic overactivity to heart failure, atrial fibrillation, and cardiometabolic disease, and examined how renal and multi-organ denervation may modify these...
Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI
In this interview from CRT 2026, Dr Eric A. Secemsky of Beth Israel Deaconess Medical Center speaks about the current status of renal denervation as a management strategy for atrial fibrillation and hypertension.
In this interview from CRT 2026, Dr Eric A. Secemsky of Beth Israel Deaconess Medical Center speaks about the current status of renal denervation as a management strategy for atrial fibrillation and hypertension.
At CRT 2026, Dr Sanjit S. Jolly of McMaster University presented the most recent developments in combination therapy for atrial fibrillation and the highly anticipated LAAOS IV trial.
At CRT 2026, Dr Sanjit S. Jolly of McMaster University presented the most recent developments in combination therapy for atrial fibrillation and the highly anticipated LAAOS IV trial.
Scientia's novel access platform is designed to improve navigability through complex anatomy and simplify neurovascular procedures. By enabling faster and more reliable access, these technologies improve procedural efficiency.
Scientia's novel access platform is designed to improve navigability through complex anatomy and simplify neurovascular procedures. By enabling faster and more reliable access, these technologies improve procedural efficiency.